Albumin Excretion Rate and Cardiovascular Risk

TABLE 1

Baseline characteristics stratified by peak response curve morphology group

Variable Group 1: normal peak Group 2: early nondominant peak Group 3: early dominant peak P for trend
n 137 93 41
Sex (% male) 43 40 64 0.06
Age (years) 53 ± 7.8 55 ± 7.0 55 ± 8.5 0.053
Ethnicity (% European) 55 44 51 0.2
Blood pressure measures
    Resting brachial systolic (mmHg) 133 ± 20 142 ± 24 146 ± 26 0.001
    Resting brachial diastolic (mmHg) 81 ± 9 84 ± 11 85 ± 11 0.01
    Ankle systolic (mmHg) 148 ± 17 155 ± 22 158 ± 26 0.002
    Ambulatory daytime systolic (mmHg) 113 ± 12 119 ± 19 122 ± 15 0.001
    Ambulatory nighttime systolic (mmHg) 104 ± 14 107 ± 17 104 ± 31 0.5
    Ankle-brachial index 1.12 ± 0.11 1.11 ± 0.11 1.09 ± 0.15 0.2
Femoral-dorsalis pedis PWV (m/s) 10.9 ± 2.0 11.4 ± 2.8 10.6 ± 2.5 0.8
Height (cm) 167 ± 9 167 ± 9 169 ± 10 0.07
Weight (kg) 81 ± 15 84 ± 16 90 ± 19 <0.001
Waist (cm) 92 ± 12 95 ± 13 99 ± 20 0.005
Fasting insulin (IU/dl)* 6.3 (4.4–9.4) 6.8 (4.3–8.7) 7.4 (4.3–18.4) 0.18
Fasting glucose (mmol/l)* 5.6 (4.9–6.0) 6.1 (4.9–6.8) 6.6 (4.9–10.1) 0.001
Cholesterol (mmol/l) 5.2 ± 0.9 5.1 ± 1.1 5.1 ± 1.3 0.7
HDL (mmol/l) 1.30 ± 0.35 1.25 ± 0.33 1.20 ± 0.35 0.08
Fasting triglyceride (mmol/l)* 1.08 (0.78–1.40) 1.15 (0.72–1.52) 1.23 (0.92–1.85) 0.1
Diabetes (%) 31 42 51 0.012
Statin therapy (%) 12 15 20 0.5
Antihypertensive therapy (%) 25 30 40 0.2
Smokers (current/ex/never) (%) 14/37/49 24/23/53 32/37/32 0.02
Peak response (au) 47.2 (33.5–69.4) 50.3 (34.9–76.2) 46.9 (34.7–70.4) 0.8
  • Data are means ± SD except where data are skewed, for which geometric mean and 25th and 75th percentiles are shown.

  • *

    * Log-transformed data. PWV, pulse wave velocity.

This Article

  1. Diabetes vol. 54 no. 6 1816-1822